Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Brogidirsen in Muscular Dystrophy, Duchenne: NCT05135663 Clinical Landscape Report 2026
28 September 2026
NCT05135663 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT05096221 Clinical Landscape Report 2026
28 September 2026
NCT05096221 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deramiocel in Muscular Dystrophy, Duchenne: NCT05126758 Clinical Landscape Report 2026
28 September 2026
NCT05126758 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vamorolone in Muscular Dystrophy, Duchenne: NCT05185622 Clinical Landscape Report 2026
28 September 2026
NCT05185622 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bocidelpar in Mitochondrial Myopathies: NCT05217901 Clinical Landscape Report 2026
28 September 2026
NCT05217901 clinical landscape for Mitochondrial Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tadalafil in Muscular Dystrophy, Duchenne: NCT05195775 Clinical Landscape Report 2026
28 September 2026
NCT05195775 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fordadistrogene movaparvovec in Muscular Dystrophy, Duchenne: NCT05429372 Clinical Landscape Report 2026
28 September 2026
NCT05429372 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Prednisolone Acetate in Muscular Dystrophy, Duchenne: NCT05412394 Clinical Landscape Report 2026
28 September 2026
NCT05412394 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EN-001 (Encell) in Muscular Dystrophy, Duchenne: NCT05338099 Clinical Landscape Report 2026
28 September 2026
NCT05338099 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CRD-TMH-001 in Muscular Dystrophy, Duchenne: NCT05514249 Clinical Landscape Report 2026
28 September 2026
NCT05514249 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zeleciment Rostudirsen in Muscular Dystrophy, Duchenne: NCT05524883 Clinical Landscape Report 2026
28 September 2026
NCT05524883 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sevasemten in Muscular Dystrophy, Duchenne: NCT05540860 Clinical Landscape Report 2026
28 September 2026
NCT05540860 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.